國家衛生研究院 NHRI:Item 3990099045/14506
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 852684      Online Users : 222
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/14506


    Title: Multi-kinase inhibitors for the treatment of asymptomatic radioactive Iodine-refractory differentiated thyroid cancer: Global non-interventional study (RIFTOS MKI)
    Authors: Brose, M;Smit, J;Lin, CC;Tori, M;Bowles, D;Worden, F;Shen, DH;Huang, SM;Tsai, HJ;Alevizaki, M;Peeters, RP;Takahashi, S;Rumyantsev, P;Guan, R;Babajanyan, S;Ozgurdal, K;Sugitani, I;Pitoia, F;Lamartina, L
    Contributors: National Institute of Cancer Research
    Abstract: BACKGROUND: Sorafenib and lenvatinib are multi-kinase inhibitors (MKI) approved for patients with radioactive iodine-refractory (RAI-R) differentiated thyroid cancer (DTC). There is no consensus on when to initiate MKI treatment. The objective of this study was to evaluate time to symptomatic progression (TTSP) in patients with RAI-R DTC for whom the decision to treat with an MKI was made at study entry. METHODS: International, prospective, open-label, non-interventional cohort study (NCT02303444). Eligible patients had asymptomatic, progressive RAI-R DTC, with ≥1 lesion ≥1 cm in diameter and life expectancy ≥6 months. The decision to treat with an MKI was at the treating physician's discretion. Primary endpoint was TTSP from study entry. Two cohorts were evaluated: patients for whom a decision to initiate an MKI was made at study entry (Cohort 1) and patients for whom there was a decision not to initiate an MKI at study entry (Cohort 2). Cohorts were compared descriptively. RESULTS: The full analysis set (FAS) comprised 647 patients from 19 countries. The median duration of observation was 35.5 months (range <1-59.4). Of 344 MKI-treated patients, 209 received sorafenib, 191 received lenvatinib, and 19 received another MKI at some point. Median TTSP was 55.4 months (interquartile range [IQR] 18.6-not estimable [NE]) overall, 55.4 months (IQR 15.2-NE) in Cohort 1 (n=169), and 51.4 months (IQR 20.0-NE) in Cohort 2 (n=478). TTSP ≥36 months was achieved in 64.5% of patients overall, 59.5% of patients in Cohort 1, and 66.4% of patients in Cohort 2. Median overall survival (OS) from classification as RAI-R was 167 months and median PFS from start of MKI therapy was 19.2 months and from start of sorafenib therapy 16.7 months. Among sorafenib-treated patients, 70% had dose modifications, 35% had a dose reduction, 89% experienced ≥1 treatment-emergent adverse event (TEAE), and 82% experienced ≥1 drug-related TEAE. CONCLUSION: This real-world study provides valuable insight into outcomes in patients with asymptomatic, progressive RAI-R DTC under observation or MKI treatment. TTSP in the FAS provides insight into the current prognosis for patients with RAI-R DTC in the era of MKIs.
    Date: 2022-09
    Relation: Thyroid. 2022 Sep;32(9):1059-1068.
    Link to: http://dx.doi.org/10.1089/thy.2022.0061
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1050-7256&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000855923000001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85138450554
    Appears in Collections:[Hui-Jen Tsai] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML170View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback